Journal
NATURE REVIEWS CLINICAL ONCOLOGY
Volume 7, Issue 1, Pages 7-8Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrclinonc.2009.173
Keywords
-
Categories
Ask authors/readers for more resources
Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-alpha as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
